drugset
drugset / Trial / NCT03946592

Evaluate the Efficacy and Safety of DWJ211 in Patient With Moderate or Severe Submental Fat

NCT03946592 ↗

Phase 3 Completed 148 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedParallel-groupTriple-blindTreatment

Summary

Evaluate the efficacy and safety of DWJ211 in patient with moderate or severe submental fat

Timeline

Start
2019-05-15
Primary completion
2020-07-02
Completion
2020-07-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Deoxycholic Acid Small molecule — Subcutaneous

Indications

No indication recorded.